» Articles » PMID: 32034397

ESC Working Group on Coronary Pathophysiology and Microcirculation Position Paper on 'coronary Microvascular Dysfunction in Cardiovascular Disease'

Abstract

Although myocardial ischaemia usually manifests as a consequence of atherosclerosis-dependent obstructive epicardial coronary artery disease, a significant percentage of patients suffer ischaemic events in the absence of epicardial coronary artery obstruction. Experimental and clinical evidence highlight the abnormalities of the coronary microcirculation as a main cause of myocardial ischaemia in patients with 'normal or near normal' coronary arteries on angiography. Coronary microvascular disturbances have been associated with early stages of atherosclerosis even prior to any angiographic evidence of epicardial coronary stenosis, as well as to other cardiac pathologies such as myocardial hypertrophy and heart failure. The main objectives of the manuscript are (i) to provide updated evidence in our current understanding of the pathophysiological consequences of microvascular dysfunction in the heart; (ii) to report on the current knowledge on the relevance of cardiovascular risk factors and comorbid conditions for microcirculatory dysfunction; and (iii) to evidence the relevance of the clinical consequences of microvascular dysfunction. Highlighting the clinical importance of coronary microvascular dysfunction will open the field for research and the development of novel strategies for intervention will encourage early detection of subclinical disease and will help in the stratification of cardiovascular risk in agreement with the new concept of precision medicine.

Citing Articles

Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.

Tang N, Li K, Li H, Zhang Q, Hao J, Qi C World J Cardiol. 2025; 17(2):103950.

PMID: 40061275 PMC: 11886395. DOI: 10.4330/wjc.v17.i2.103950.


Physiological Mechanisms Driving Microcirculatory Enhancement: the Impact of Physical Activity.

Li J, Liu G, Zhang D, Zhang K, Cao C Rev Cardiovasc Med. 2025; 26(2):25302.

PMID: 40026510 PMC: 11868893. DOI: 10.31083/RCM25302.


The Role of Circulating Biomarkers in Patients with Coronary Microvascular Disease.

Quarta R, Martino G, Romano L, Lopes G, Greco F, Spaccarotella C Biomolecules. 2025; 15(2).

PMID: 40001480 PMC: 11853534. DOI: 10.3390/biom15020177.


Association between segmental noninvasive longitudinal strain and quantitative microvascular perfusion in ST-segment elevation myocardial infarction: implications for clinical outcomes.

Zhang R, Liang S, Zhao F, Du B, Wang R, Shi W BMC Cardiovasc Disord. 2025; 25(1):109.

PMID: 39966701 PMC: 11834631. DOI: 10.1186/s12872-025-04547-5.


Predictive value of angiographic microvascular resistance for left ventricular thrombus in anterior ST-segment elevation myocardial infarction.

Wu Z, Ma C, Wang Y, Li G, Mu D, Wang L Int J Cardiovasc Imaging. 2025; 41(3):603-614.

PMID: 39953312 PMC: 11880151. DOI: 10.1007/s10554-025-03351-8.


References
1.
Cenko E, van der Schaar M, Yoon J, Kedev S, Valvukis M, Vasiljevic Z . Sex-Specific Treatment Effects After Primary Percutaneous Intervention: A Study on Coronary Blood Flow and Delay to Hospital Presentation. J Am Heart Assoc. 2019; 8(4):e011190. PMC: 6405653. DOI: 10.1161/JAHA.118.011190. View

2.
Ge L, Zhou X, Ji W, Lu R, Zhang Y, Zhang Y . Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J Physiol Heart Circ Physiol. 2014; 308(5):H500-9. DOI: 10.1152/ajpheart.00381.2014. View

3.
Crea F, Camici P, Merz C . Coronary microvascular dysfunction: an update. Eur Heart J. 2013; 35(17):1101-11. PMC: 4006091. DOI: 10.1093/eurheartj/eht513. View

4.
Gehrie E, Reynolds H, Chen A, Neelon B, Roe M, Gibler W . Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with.... Am Heart J. 2009; 158(4):688-94. DOI: 10.1016/j.ahj.2009.08.004. View

5.
Yun J, Park Y, Cha S, Ahn Y, Ko S . Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes. Cardiovasc Diabetol. 2018; 17(1):109. PMC: 6071370. DOI: 10.1186/s12933-018-0752-6. View